Results from 317 newly diagnosed DMARD-naive patients with rheumatoid arthritis enrolled in the U-Act-Early trial show a clear reduction in the progression of bone erosions after 104 weeks of treatment with tocilizumab alone or in combination with methotrexate compared with treatment with methotrexate alone (P ≤ 0.023). The proportion of patients who showed no progression of erosions was also higher among those taking tocilizumab than methotrexate alone at weeks 52 and 104.